Journal article
Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women
N Munoz, SK Kjaer, K Sigurdsson, OE Iversen, M Hernandez-Avila, CM Wheeler, G Perez, DR Brown, LA Koutsky, EH Tay, PJ Garcia, KA Ault, SM Garland, S Leodolter, SE Olsson, GWK Tang, DG Ferris, J Paavonen, M Steben, FX Bosch Show all
Journal of the National Cancer Institute | Published : 2010
DOI: 10.1093/jnci/djp534
Abstract
Background The impact of the prophylactic vaccine against human papillomavirus (HPV) types 6, 11, 16, and 18 (HPV6/11/16/18) on all HPV-associated genital disease was investigated in a population that approximates sexually naive women in that they were "negative to 14 HPV types" and in a mixed population of HPV-exposed and-unexposed women (intention-to-treat group).MethodsThis analysis studied 17 622 women aged 15-26 years who were enrolled in one of two randomized, placebo-controlled, efficacy trials for the HPV6/11/16/18 vaccine (first patient on December 28, 2001, and studies completed July 31, 2007). Vaccine or placebo was given at day 1, month 2, and month 6. All women underwent cervico..
View full abstract